Lung Cancer Therapy OK'd for Once 'Undruggable' Target

(MedPage Today) -- The FDA granted accelerated approval to sotorasib (Lumakras) on Friday as a second-line agent for non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations.
Sotorasib becomes the first approved agent targeting any KRAS...